Posts

Disc Medicine reports promising early PV data

on
Disc Medicine reported initial Phase 2 RESTORE-PV results for DISC-3405 in polycythemia vera, a rare blood cancer, at the 2026 Society of Hematologic Oncology meeting. Among 13 patients completing 26 weeks, average phlebotomies fell from 4.0 in the preceding 26 weeks to 0.6 after treatment; 61.5% remained phlebotomy-free through week 26. Mean hematocrit stayed below 45%, with early symptom improvement. DISC-3405 increased hepcidin, reduced serum iron, and was generally well tolerated; reported injection-site reactions were mild and temporary. The results are preliminary: efficacy data came from a small Cohort A subgroup, while broader and longer-term data are still pending. Disc Medicine expects additional RESTORE-PV and sickle-cell data by the end of 2026. Separately, Frazier Life Sciences said it added more than $1.1 billion in new commitments to its evergreen Public Fund, bringing the fund to roughly $2.8 billion. The fund invests in publicly traded biotechnology and healt...

Major Novartis shareholder calls for board shake-up after trial setbacks

on

FDA Places Partial Hold on Biohaven’s Epilepsy Drug After $350 Million Licensing Deal

on

FDA expands Bayer’s Hyrnuo into first-line HER2-mutant lung cancer

on

FDA signals flexibility on psychedelic drug review while keeping evidence standards

on

FDA makes acting CBER and CDER leaders permanent

on

Encoded closes $275M Series F to advance Dravet syndrome drug ETX101

on

Tyra shares slide after bladder-cancer drug misses investor efficacy bar

on

Tyra’s bladder-cancer data offer a bright spot—but miss investor expectations

on

Beeline’s oral lupus drug afimetoran delivers positive Phase 2 results

on

Drug-pricing policy upheaval forces pharma companies to rethink global launch strategies

on

Evommune abandons hope for EVO756 as an itch drug after latest Phase 2 failure

on

FDA Makes CDER and CBER Leadership Permanent While Commissioner Nominee Awaits Senate Confirmation

on